candesartan has been researched along with Nephrosclerosis in 2 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Nephrosclerosis: Hardening of the KIDNEY due to infiltration by fibrous connective tissue (FIBROSIS), usually caused by renovascular diseases or chronic HYPERTENSION. Nephrosclerosis leads to renal ISCHEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We describe a hypertensive nephrosclerosis patient presenting with severe hyperkalemia due to a combination therapy of the angiotensin receptor blocker (ARB) candesartan and spironolactone despite mildly decreased renal function." | 7.73 | Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone. ( Fujii, H; Inenaga, T; Kawano, Y; Nakahama, H; Nakamura, S; Yoshihara, F, 2005) |
| "We describe a hypertensive nephrosclerosis patient presenting with severe hyperkalemia due to a combination therapy of the angiotensin receptor blocker (ARB) candesartan and spironolactone despite mildly decreased renal function." | 3.73 | Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone. ( Fujii, H; Inenaga, T; Kawano, Y; Nakahama, H; Nakamura, S; Yoshihara, F, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirayama, T | 1 |
| Takahashi, F | 1 |
| Kikuchi, K | 1 |
| Fujii, H | 1 |
| Nakahama, H | 1 |
| Yoshihara, F | 1 |
| Nakamura, S | 1 |
| Inenaga, T | 1 |
| Kawano, Y | 1 |
1 review available for candesartan and Nephrosclerosis
| Article | Year |
|---|---|
[Secondary nephrotic syndrome due to cardiovascular disease].
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diagnosis, Differential | 2004 |
1 other study available for candesartan and Nephrosclerosis
| Article | Year |
|---|---|
Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diuretics; Drug Therapy | 2005 |